Abstract
Abstract
Purpose
To predict the course of immune recovery (IR) in HIV-1-infected patients after initiation of combined antiretroviral therapy (cART) by determination of the plasma concentration of Torque Teno Virus (TTV).
TTV has been identified as marker for risk assessment in immunosuppressed patients after transplantation procedures. Here, TTV was analyzed in HIV-1-infected therapy-naïve patients to evaluate its use as predictor of the course of IR for guidance of individualized treatment.
Methods
TTV DNA was quantified in plasma samples of 301 therapy-naïve HIV-1-infected patients and correlated to CD4+ cell count, HIV viral load, presence of the herpes viruses CMV, EBV and HHV-8, age and sex. Patients were classified according to their initial CD4+ cell count and to the extent of CD4+ T-cell increase within the first year of cART.
Results
TTV DNA was detectable in 96% of the patients’ plasma samples with a median TTV plasma concentration of 5.37 log10 cop/ml. The baseline CD4+ cell count was negatively correlated with TTV plasma concentration (p = 0.003). In patients with a CD4+ cell recovery < 50 cells/µl, the median TTV plasma concentration was significantly higher compared to patients with a CD4+ cell recovery of > 200 CD4+ cells/µl (5.68 log10 cop/ml versus 4.99 log10 cop/ml; p = 0.011). TTV plasma concentration in combination with baseline CD4+ cell count were significantly correlated to CD4+ cell recovery (p = 0.004). For all other parameters considered, no significant correlation for CD4+ cell recovery was found.
Conclusion
Within the cohort, the significantly elevated TTV plasma concentration in patients with diminished CD4+ cell recovery indicates a more profound immune defect. Baseline TTV plasma concentrations and CD4+ cell count are predictive for the course of immune recovery in HIV-1-infected patients with severe immunodeficiency.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference48 articles.
1. Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256–66.
2. Degli Antoni A, Weimer LE, Fragola V, Giacometti A, Sozio F. A reduction grade of lipodystrophy and limited side effects after HAART regimen with raltegravir, lamivudine, darunavir and ritonavir in an HIV-1 infected patient after six years of antiretroviral therapy. West Indian Med J. 2015;64(3):291–3.
3. Khan NH, Kohli M, Gupta K, Das BK, Pandey RM, Sinha S. HIV drug resistance mutations in patients with HIV and HIV-TB coinfection after failure of first-line therapy: a prevalence study in a resource-limited setting. J Int Assoc Provid AIDS Care. 2019. https://doi.org/10.1177/2325958219849061.
4. Archampong T, Ojewale O, Bears K, Chen Y, Lartey M, Sagoe KW, et al. Brief report: relationship between ABCC4 SNPs and hepatitis B virus suppression during tenofovir-containing antiretroviral therapy in patients with HIV/HBV coinfection. J Acquir Immune Defic Syndr. 2019;82(4):421–5.
5. Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG. Pharmacotherapy and treatment options for HIV-associated nephropathy. Expert Opin Pharmacother. 2018;19(1):39–48.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献